August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...

By David Stephen The sweeping and aggressive cuts to research funding at the National Institutes of Health [NIH] suggests that it may be likely that several of the Institutes and […] ...

Held in March 2025 under the EMPOWER-TZ program, funded by the Fogarty International Center at National Institutes of Health (NIH), the symposium was organized by the Johns Hopkins Schools of Medicine ...

As continued cuts to federal scientific research funding persist, it becomes difficult to parse out the impacts. However, one particular impact is clear: the budget reduction plans will have short and ...